Mammaprint Study Spares Breast Cancer Patients Chemo

MammaPrint Study Spares Breast Cancer Patients Chemo

Pink Lotus Power Up

MammaPrint Identifies Which Breast Cancer Patients Can Bypass Chemotherapy

KPIX | CBS NEWS BAY AREA

MammaPrint genetic testing reduces chemotherapy overtreatment in breast cancer patients

Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT

NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer

MammaPrint® - Agendia’s Risk Of Recurrence Test

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in br...

Ian Grady, MD FACS Presents MammaPrint & BluePrint Case Study on 73-year-old ER+ BASAL Patient

Gene test finds which breast cancer patients can skip chemo

Study: Many Breast Cancer Patients Can Skip Chemotherapy

Dealing with an "intermediate" breast cancer recurrence score?

Ian Grady, MD FACS speak on MammaPrint And It's Predictive To Chemotherapy Response

Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast Cancer

Gene test spares cancer patient from chemo

ABC Action News

Patient Experiences with MammaPrint®

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence

Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy

ABC Action News

Breast Cancer Test, Breast Cancer Awareness - Agendia & MammaPrint

Angie's Story